Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vejle Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed non-small cell lung cancer, including squamous cell carcinomas, adenocarcinomas and non-neuroendocrine large cell carcinomas
Patients with advanced stages of NSCLC who are candidates to first-line platinum-based doublet chemotherapy
Measurable disease by RECIST 1.1
Age ≥ 18 years.
Performance status 0-2.
Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion):
* White blood cells (WBC) ≥ 3.0 \* 10\^9/l or neutrophils (ANC) ≥ 1.5 \* 10\^9/l
* Platelet count ≥ 100 \* 10\^9/l
* Hemoglobin ≥ 6 mmol/l
* Serum bilirubin \< 2.0 \* upper level of normal (ULN)
* Serum transaminase ≤ 2.5 \* ULN
* Serum creatinine ≤ 1.5 ULN
Written and orally informed consent.
You may not be if
Other malignant diseases within 5 years prior to inclusion in the study, except curatively treated basal cell or squamous cell carcinoma of the skin and other types of cancer with minimal risk of recurrence.
Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation.
Patients who have received prior chemotherapy for NSCLC
Patients with NSCLC who are candidates to neoadjuvant chemotherapy or curative chemoradiotherapy
Underlying disease not adequately treated (diabetes, cardiac disease)
Allergy to the active substance or any of the auxiliary agents
Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory.
Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment.
